nach oben

Erschienen in:

01.07.2011 | Clinical Trial

Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer

verfasst von: Michael A. Jacobs, Ronald Ouwerkerk, Antonio C. Wolff, Edward Gabrielson, Hind Warzecha, Stacie Jeter, David A. Bluemke, Richard Wahl, Vered Stearns

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

We prospectively investigated using advanced magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) to identify radiological biomarkers for treatment response in patients receiving preoperative systemic therapy (PST) for locally advanced breast cancer. Patients with a stage II or III breast cancer receiving PST were selected and underwent positron emission tomography (PET), magnetic resonance imaging (MRI), and breast biopsies at baseline and after the first cycle of PST (days 7–8) during the full course of treatment. PET/CT was acquired after injection of 2-deoxy-2-[18F]-fluoro-d-glucose (¹⁸FDG, 0.22 mCi/kg) and quantified with standardized uptake value assessment (SUV). Diagnostic breast MRI and sodium (²³Na) was acquired at 1.5 T. Total tissue sodium concentration (TSC), response criteria in solid tumors (RECIST), and volumes were quantified. Treatment response was determined by pathological assessment at surgery. Immunohistochemistry values of the proliferative index (Ki-67) were performed on biopsy specimens. Six of nineteen eligible women (43 ± 11 years) who received PST underwent radiological imaging of ¹⁸FDG-PET/CT and MRI for at least two cycles of treatment. Five patients had a pathological partial response (pPR) and one had pathological non-response (pNR). TSC decreased 21% in responders with increases in the non-responder (P = 0.03). Greater reduction in SUV was observed in responders (38%) compared to the non-responder (22%; P = 0.03). MRI volumes decreased after cycle 1 by 42% (responders) and 35% (non-responder; P = 0.11). Proliferation index Ki-67 declined in responders in the first cycle (median = 47%, range = 29–20%), but increased (4%) in the non-responder. Significant decreases in TSC, SUV, and Ki-67 were observed in responders with increases in TSC and Ki-67 in non-responders. Our results demonstrate the feasibility of using multi-modality proton, ²³Na MRI, and PET/CT metrics as radiological biomarkers for monitoring response to PST in patients with operable breast cancer.

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300PubMedCrossRef

Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L et al (2008) Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol 26(5):806–813PubMedCrossRef

Lehman CD, Gatsonis C, Kuhl CK, Hendrick RE, Pisano ED, Hanna L, Peacock S, Smazal SF, Maki DD, Julian TB et al (2007) MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 356(13):1295–1303PubMedCrossRef

El Khouli RH, Jacobs MA, Bluemke DA (2008) Magnetic resonance imaging of the breast. Semin Roentgenol 43(4):265–281PubMedCrossRef

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM (2005) MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol 184(6):1774–1781PubMed

Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, Pickles MD, Tozer DJ, Turnbull LW (2006) Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 94(3):427–435PubMedCrossRef

Yu HJ, Chen JH, Mehta RS, Nalcioglu O, Su MY (2007) MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J Magn Reson Imaging 26(3):615–623PubMedCrossRef

Baek HM, Chen JH, Nie K, Yu HJ, Bahri S, Mehta RS, Nalcioglu O, Su MY (2009) Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 251(3):653–662PubMedCrossRef

Jacobs MA, Stearns V, Wolff AC, Barker PB, Tsangaris T, Argani P, Davidson NE, Bhujwalla ZM, Bluemke DA, Ouwerkerk R (2010) Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol 17(12):1477–1485PubMedCrossRef

10.

Wahl RL (1998) Positron emission tomography (PET): an update on applications in breast cancer. Breast Dis 10(3–4):165–175PubMed

11.

Kim SJ, Kim SK, Lee ES, Ro J, Kang S (2004) Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 15(9):1352–1357PubMedCrossRef

12.

Kelloff G, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, Cheson BD, O’Shaughnessy J, Guyton KZ, Mankoff DA et al (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11(8):2785–2808PubMedCrossRef

13.

Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL (2006) Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 33(3):254–262PubMedCrossRef

14.

Chen X, Moore MO, Lehman CD, Mankoff DA, Lawton TJ, Peacock S, Schubert EK, Livingston RB (2004) Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol 11(10):1115–1124PubMedCrossRef

15.

Iagaru A, Masamed R, Keesara S, Conti PS (2007) Breast MRI and 18F FDG PET/CT in the management of breast cancer. Ann Nucl Med 21(1):33–38PubMedCrossRef

16.

Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, Boichot C, Cochet A, Fumoleau P, Brunotte F (2007) [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 34(12):1915–1924PubMedCrossRef

17.

Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(suppl 1):122S–150S

18.

Moy L, Ponzo F, Noz ME, Maguire GQ Jr, Murphy-Walcott AD, Deans AE, Kitazono MT, Travascio L, Kramer EL (2007) Improving specificity of breast MRI using prone PET and fused MRI and PET 3D volume datasets. J Nucl Med 48(4):528–537PubMedCrossRef

19.

Ouwerkerk R, Jacobs MA, Macura KJ, Wolff AC, Stearns V, Mezban SD, Khouri NF, Bluemke DA, Bottomley PA (2007) Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive (23)Na MRI. Breast Cancer Res Treat 106(2):151–160PubMedCrossRef

20.

Boada FE, Gillen JS, Shen GX, Chang SY, Thulborn KR (1997) Fast three dimensional sodium imaging. Magn Reson Med 37(5):706–715PubMedCrossRef

21.

Jacobs MA, Knight RA, Windham JP, Zhang ZG, Soltanian-Zadeh H, Goussev AV, Peck DJ, Chopp M (1999) Identification of cerebral ischemic lesions in rat using eigenimage filtered magnetic resonance imaging. Brain Res 837(1–2):83–94PubMedCrossRef

22.

El Khouli RH, Macura KJ, Jacobs MA, Khalil T, Kamel I, Dwyer A, Bluemke DA (2009) Dynamic contrast enhanced magnetic resonance imaging of the breast: quantitative method for kinetic curve type assessment. Am J Roentgenol 196(4):W295–W300CrossRef

23.

Therasse P, Eisenhauer EA, Verweij J (2006) RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42(8):1031–1039PubMedCrossRef

24.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228PubMedCrossRef

25.

Thie JA (2004) Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 45(9):1431–1434PubMed

26.

Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34(9):1339–1347PubMedCrossRef

27.

McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI, Smith TA, Hutcheon AW, Miller ID, Smith IC et al (2007) Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat 102(1):75–84PubMedCrossRef

28.

Jaffe CC (2008) Response assessment in clinical trials: implications for sarcoma clinical trial design. Oncologist 13(suppl 2):14–18PubMedCrossRef

29.

Van den Abbeele AD (2008) The lessons of GIST–PET and PET/CT: a new paradigm for imaging. Oncologist 13(suppl 2):8–13PubMedCrossRef

30.

Sharma U, Danishad KK, Seenu V, Jagannathan NR (2009) Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 22(1):104–113PubMedCrossRef

31.

Danishad KK, Sharma U, Sah RG, Seenu V, Parshad R, Jagannathan NR (2010) Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed 23(3):233–241PubMed

32.

Ei Khouli RH, Jacobs MA, Mezban SD, Huang P, Kamel IR, Macura KJ, Bluemke DA (2010) Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology 256(1):64–73PubMedCrossRef

33.

Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F, Nathrath W, Schwaiger M (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42(1):9–16PubMed

34.

MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM (1996) Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 74(9):1458–1465PubMedCrossRef

35.

Ouwerkerk R, Bottomley PA, Solaiyappan M, Spooner AE, Tomaselli GF, Wu KC, Weiss RG (2008) Tissue sodium concentration in myocardial infarction in humans: a quantitative 23Na MR imaging study. Radiology 248(1):88–96PubMedCrossRef

36.

Jacobs MA, Ouwerkerk R, Kamel I, Bottomley PA, Bluemke DA, Kim HS (2009) Proton, diffusion-weighted imaging, and sodium ((23)Na) MRI of uterine leiomyomata after MR-guided high-intensity focused ultrasound: a preliminary study. J Magn Reson Imaging 29(3):649–656PubMedCrossRef

37.

Mellon EA, Pilkinton DT, Clark CM, Elliott MA, Witschey WR 2nd, Borthakur A, Reddy R (2009) Sodium MR imaging detection of mild Alzheimer disease: preliminary study. AJNR Am J Neuroradiol 30(5):978–984PubMedCrossRef

Titel: Monitoring of neoadjuvant chemotherapy using multiparametric, 23Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer
verfasst von: Michael A. Jacobs
Ronald Ouwerkerk
Antonio C. Wolff
Edward Gabrielson
Hind Warzecha
Stacie Jeter
David A. Bluemke
Richard Wahl
Vered Stearns
Publikationsdatum: 01.07.2011
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-011-1442-1

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2011

Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994–1998 and 2003–2006

Trends in return to work of breast cancer survivors

Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening

Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer

Is RAD51 135G>C polymorphism really associated with breast cancer in general population? Biased design and results lead to inappropriate conclusion

Multiple foci of invasive breast cancer: can breast MRI influence surgical management?

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie